Search

Patient safety and blood transfusion: new solutions.

Interesting paper on new solutions for making transfusions safer. The only aspect which is missing is a better education of the staff involved in hemotherapy, which is even more important than monitoring, etc. – Volker Kretschmer

Managing uncontrolled hemorrhage in trauma and surgery: a novel and promising approach.

This is an introduction for a supplement to the Canadian Journal of Anesthesia reporting proceedings of a satellite symposium presented at the 2002 Canadian Anesthesiologists’ Society Annual Meeting. It highlights the role of rFVIIa in managing bleeding in hemophilia patients with inhibitors, and the increasing number of case reports and studies in its role in […]

Continuous infusion of coagulation factor products.

This is an interesting review on the use of continuous infusion of coagulation factor products over the last 11 years. It concludes that effects were favorable in comparison to intermittent bolus infusions. It suggests that continuous infusion has the advantage of maintaining a therapeutic level of the factor, and is associated with decrease in factor […]

Experience with use of recombinant activated factor VII.

This is a case report of successfully treating hemorrhage with rFVIIa in four patients with factor VIII and one with factor V inhibitor. One patient was initially treated with APCC (Autoplex) and blood products unsuccessfully. The authors confirm the efficacy and safety of rFVIIa and suggest carrying out cost effectiveness analysis. Further information is required […]

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage.

This article reports 2 patients with severe thrombocytopenia and severe hemorrhage which did not respond to standard therapy and platelet transfusion, but responded quickly to administration of a single dose of rFVIIa. The first patient had Waldenstoms macroglobulinemia and immune thrombocytopenia, and the second one had acute lymphoblastic leukemia. No adverse effects for rFVIIa were […]

Iron administration and clinical outcomes in hemodialysis patients.

This study raises two important questions: First, are the observed adverse events upon high dose iron dextran users due to confounding variables such as comorbidity, or are they true iron dextran effects? Second, if they are true iron dextran effects, are they caused by the iron or the dextran? – C. Gasche.

Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients.

The authors from Taiwan state that they used “Ferrum Hausmann, a ferric polymaltose complex.” Under the same name (Ferrum Hausmann), iron saccharate (identical to iron sucrose) has been licensed in several European countries. The confusion concerning various iron sugar compounds gets even greater when one considers that “ferric polymaltose complex” was reported as being used […]

Surgery-associated acquired hemophilia A.

This article raises awareness of the occurrence of acquired FVIII inhibitor postoperatively. One patient developed an inhibitor to FVIII 4 days after surgery for correction of abdominal hernia and bleeding was treated successfully with rFVIIa and immunosuppression. The second patient had severe bleeding 14 days post cholecystectomy due to an acquired FVIII inhibitor, but diagnosis […]